BiotechTube

FD MVA-BN

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Jun 19, 2019 → Jun 22, 2020

NCT ID
NCT03699124

About FD MVA-BN

FD MVA-BN is a phase 3 stage product being developed by Bavarian Nordic for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT03699124. Target conditions include Smallpox.

What happened to similar drugs?

3 of 7 similar drugs in Smallpox were approved

Approved (3) Terminated (0) Active (4)
🔄IMVAMUNE®Bavarian NordicPhase 3
🔄ACAM2000Emergent BioSolutionsPhase 3
✅Vaccination with ACAM2000Emergent BioSolutionsApproved
🔄tecovirimatSIGA TechnologiesPhase 3
✅Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletSIGA TechnologiesApproved
🔄TPOXXSIGA TechnologiesPhase 3
✅TpoxxSIGA TechnologiesApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03699124Phase 3Completed

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
35
MVA (smallpox vaccine)SanofiPhase 1
21
ACAM3000 MVA VaccineSanofiPhase 1
29
MVA Smallpox vaccine + PlaceboSanofiPhase 2
35
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
27
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
32
MVA-BNBavarian NordicPhase 1
26
IMVAMUNE®Bavarian NordicPhase 2
32
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
32
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
IMVAMUNE®Bavarian NordicPhase 3
37
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
32
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
32
Elstree-BNBavarian NordicPhase 1
26
ACAM2000Emergent BioSolutionsPhase 3
30
VIGIVEmergent BioSolutionsPre-clinical
23
ACAM2000® smallpox vaccineEmergent BioSolutionsPre-clinical
16
BrincidofovirEmergent BioSolutionsPhase 1
19
Vaccination with ACAM2000Emergent BioSolutionsApproved
33